2. Membrane Transporter/Ion Channel Neuronal Signaling
  3. GABA Receptor
  4. Tracazolate

Tracazolate (ICI 136753) is an orally active non-benzodiazepine anxiolytic. Tracazolate significantly enhances the binding of the radioligand 3H-flunitrazepam (3H-FLU) to brain tissue benzodiazepine receptors. Tracazolate enhances the binding of γ-aminobutyric acid (GABA) to its receptors. Tracazolate exhibits anticonvulsant activity. Tracazolate can be used in anxiety-related research.

For research use only. We do not sell to patients.

Tracazolate

Tracazolate Chemical Structure

CAS No. : 41094-88-6

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other In-stock Forms of Tracazolate:

Other Forms of Tracazolate:

Tracazolate Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Tracazolate (ICI 136753) is an orally active non-benzodiazepine anxiolytic. Tracazolate significantly enhances the binding of the radioligand 3H-flunitrazepam (3H-FLU) to brain tissue benzodiazepine receptors. Tracazolate enhances the binding of γ-aminobutyric acid (GABA) to its receptors. Tracazolate exhibits anticonvulsant activity. Tracazolate can be used in anxiety-related research[1][2].

In Vitro

Tracazolate enhances the binding of [3H]flunitrazepam to benzodiazepine receptor sites in mammalian brain tissue[1].
Tracazolate enhances the binding of [3H]GABA to its receptor sites in mammalian brain tissue[1].
Tracazolate enhances the binding of [3H]flunitrazepam to brain tissue[2].
Tracazolate enhances GABA binding to rat brain membrane fractions[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Tracazolate Related Antibodies
In Vivo

Tracazolate (10-80 mg/kg; i.p.; p.o.; single administration) exhibits dose-dependent anxiolytic activity in rat shock-induced drinking suppression tests, with a relative potency of 1/4 to 1/2 that of Chlordiazepoxide[1].
At all tested doses, Tracazolate (5-40 mg/kg; i.p.; p.o.; single administration) produces no statistically significant anxiolytic activity in the rat Geller conflict test[1].
Tracazolate (40-80 mg/kg; p.o.; once daily; for 12 consecutive days) shows no tolerance to its anxiolytic activity after intragastric administration at 40 or 80 mg/kg once daily for 12 consecutive days in rats[1].
Tracazolate (25-200 mg/kg; oral administration; single dose) exhibits dose-dependent anxiolytic activity in the mouse exploratory conflict test, with a minimum effective dose of 25 mg/kg p.o[1].
Tracazolate (i.p.; single administration) acts as a weak antagonist against Metrazol- and Bicuculline (HY-N0219)-induced convulsions in mice, with an i.p. ED50 of 27.7 mg/kg and 22.5 mg/kg, respectively[1].
Tracazolate (oral administration; single dose) impairs the rotarod performance of mice at high doses, with an oral ED50 of 117.1 mg/kg[1]
Tracazolate (oral administration; single dose) does not impair rotarod performance in rats when administered at doses up to 400 mg/kg via intragastric gavage[1].
Tracazolate (12.5-100 mg/kg; p.o.; single administration) does not significantly exacerbate ethanol-induced impairment in the rotarod test in mice, even at an intragastric dose as high as 100 mg/kg[1].
Tracazolate (12.5-50 mg/kg; p.o.; single administration) enhances ethanol-induced sleep duration in mice at oral doses of 25 mg/kg and above, and its minimum effective dose is comparable to that for anxiolytic effects[1].
Tracazolate (5-10 mg/kg; p.o.; single administration) potentiates the anxiolytic activity of Chlordiazepoxide in a rat model of shock-induced feeding inhibition[1].
Tracazolate (12.5 mg/kg; intraperitoneal injection; single administration) enhances the anticonvulsant activity of chlordiazepoxide in mice, reducing the ED50 of Chlordiazepoxide by approximately 6-fold[1].
Tracazolate (20-40 mg/kg; i.p.; single administration) does not increase water intake in non-water-deprived rats, nor does it do so at i.p. doses of 20 or 40 mg/kg, indicating that its anxiolytic activity is independent of drive[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Wistar (male, 180-220 g)[1]
Dosage: 10 mg/kg; 20 mg/kg; 40 mg/kg; 80 mg/kg
Administration: i.p.; p.o.; single dose
Result: Produced a statistically significant dose-dependent increase in mean number of shocks taken.
Had a relative potency of 1/4 to 1/2 that of chlordiazepoxide.
Animal Model: Sprague-Dawley (male, 240-260 g, maintained at ~80% free-feeding weight)[1]
Dosage: 5 mg/kg; 10 mg/kg; 20 mg/kg; 40 mg/kg
Administration: i.p.; p.o.; single dose
Result: Produced non-significant increases in punished responding of +7.7% (5 mg/kg i.p.), +2.1% (10 mg/kg i.p.), and +29.0% (20 mg/kg i.p.).
Produced a +126.6% increase in punished responding at 40 mg/kg p.o. that did not reach statistical significance.
Animal Model: Wistar (male, 180-220 g)[1]
Dosage: 40 mg/kg; 80 mg/kg
Administration: p.o.; daily; 12 days
Result: Retained statistically significant anxiolytic activity, with mean shocks taken of 9.95 (40 mg/kg) and 10.16 (80 mg/kg).
Animal Model: Swiss-Webster (male, 18-25 g)[1]
Dosage: 25 mg/kg; 50 mg/kg; 100 mg/kg; 200 mg/kg
Administration: p.o.; single dose
Result: Reached a minimal effective dose (MED) of 25 mg/kg p.o., which produced a statistically significant increase in mean number of shocks taken.
Animal Model: Swiss-Webster (male, 18-25 g)[1]
Dosage: ED50 27.7 mg/kg (95% confidence limits 19.4-38.4)
Administration: i.p.; single dose
Result: Had an ED50 of 27.7 mg/kg i.p. (95% confidence limits 19.4-38.4) for protection against metrazol-induced convulsions.
Animal Model: Swiss-Webster (male, 18-25 g)[1]
Dosage: ED50 22.5 mg/kg (95% confidence limits 8.9-51.9)
Administration: i.p.; single dose
Result: Had an ED50 of 22.5 mg/kg i.p. (95% confidence limits 8.9-51.9) for protection against bicuculline-induced convulsions.
Animal Model: Swiss-Webster (male, 18-25 g)[1]
Dosage: ED50 117.1 mg/kg (95% confidence limits 85.0-191.1)
Administration: p.o.; single dose
Result: Had an ED50 of 117.1 mg/kg p.o. (95% confidence limits 85.0-191.1) for impairment of rotorod performance.
Animal Model: Wistar (male, 180-220 g)[1]
Dosage: 400 mg/kg
Administration: p.o.; single dose
Result: Failed to significantly impair rotorod performance at the highest tested dose of 400 mg/kg p.o.
Animal Model: Swiss-Webster (male, 18-25 g)[1]
Dosage: 12.5 mg/kg; 25 mg/kg; 50 mg/kg; 100 mg/kg
Administration: p.o.; single dose
Result: Did not significantly enhance ethanol-induced rotorod impairment; ataxia rates were 0.0%, 0.0%, 16.7%, and 16.7% respectively.
Animal Model: Swiss-Webster (male, 18-25 g)[1]
Dosage: 12.5 mg/kg; 25 mg/kg; 50 mg/kg
Administration: p.o.; single dose
Result: Reached a minimal effective dose of 25 mg/kg p.o., which produced a statistically significant prolongation of ethanol-induced sleeptime to 59.9 minutes.
Prolonged sleeptime to 95.0 minutes at 50 mg/kg p.o.
Had no significant effect at 12.5 mg/kg p.o.
Animal Model: Wistar (male, 180-220 g)[1]
Dosage: 5 mg/kg; 10 mg/kg
Administration: p.o.
Result: Produced statistically significant increases in mean number of shocks taken when combined with chlordiazepoxide 2.5 mg/kg p.o. (a sub-effective dose alone), with a potentiative effect greater than the sum of individual drug effects.
Animal Model: Swiss-Webster (male, 18-25 g)[1]
Dosage: 12.5 mg/kg
Administration: i.p.
Result: Reduced the ED50 of chlordiazepoxide for protection against metrazol-induced convulsions from 4.9 mg/kg p.o. to 0.8 mg/kg p.o., making chlordiazepoxide approximately 6 times more potent.
Animal Model: Wistar (male, 180-220 g)[1]
Dosage: 20 mg/kg; 40 mg/kg
Administration: i.p.
Result: Did not enhance water consumption; mean lick counts were 246.5 and 222.14 respectively, which were not significantly different from controls.
Molecular Weight

304.39

Formula

C16H24N4O2
CAS No.
SMILES

O=C(OCC)C1=C(N=C2C(C=NN2CC)=C1NCCCC)C
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Tracazolate Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Tracazolate41094-88-6ICI 136753ICI136753ICI-136753GABA ReceptorGamma-aminobutyric acid Receptorγ-Aminobutyric acid Receptorconvulsionsrat brain membrane fractionsratsGeller Conflict testmiceShock-induced Suppression of Drinking testanxietyGABA receptorsbenzodiazepine receptorsmammalian brain tissueInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Tracazolate
Cat. No.:
HY-B1803
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.